Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A peripheral inhibitor of the enzyme dopa-decarboxylase which transforms levodopa into dopamine.
Its only medical use is to associate it with levodopa in the treatment of Parkinson's disease in order to block the peripheral effects of levodopa by becoming dopamine (nausea, vomiting, arrhythmias) and allowing more levodopa to reach the brain and levodopa can be given at a lower dose.
Carbidopa does not cross the blood-brain barrier, so it has no effects at the level of the central nervous system.
Oral administration 3 to 4 times a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its wide volume of distribution and short half-life make it unlikely it will transfer into breastmilk in significant amounts.
Carbidopa increases prolactin levels (Masturzo 1979, Brown 1976) and inhibits the suppressive effects of levodopa on prolactin (Camanni 1978).
See below the information of this related product: